[go: up one dir, main page]

GB202311050D0 - GP130 antigen-binding molecules - Google Patents

GP130 antigen-binding molecules

Info

Publication number
GB202311050D0
GB202311050D0 GBGB2311050.5A GB202311050A GB202311050D0 GB 202311050 D0 GB202311050 D0 GB 202311050D0 GB 202311050 A GB202311050 A GB 202311050A GB 202311050 D0 GB202311050 D0 GB 202311050D0
Authority
GB
United Kingdom
Prior art keywords
antigen
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2311050.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VVB Bio Pte Ltd
Original Assignee
VVB Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VVB Bio Pte Ltd filed Critical VVB Bio Pte Ltd
Priority to GBGB2311050.5A priority Critical patent/GB202311050D0/en
Publication of GB202311050D0 publication Critical patent/GB202311050D0/en
Priority to PCT/EP2024/070399 priority patent/WO2025017127A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
GBGB2311050.5A 2023-07-19 2023-07-19 GP130 antigen-binding molecules Ceased GB202311050D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2311050.5A GB202311050D0 (en) 2023-07-19 2023-07-19 GP130 antigen-binding molecules
PCT/EP2024/070399 WO2025017127A1 (en) 2023-07-19 2024-07-18 Gp130 antigen-binding antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2311050.5A GB202311050D0 (en) 2023-07-19 2023-07-19 GP130 antigen-binding molecules

Publications (1)

Publication Number Publication Date
GB202311050D0 true GB202311050D0 (en) 2023-08-30

Family

ID=87758645

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2311050.5A Ceased GB202311050D0 (en) 2023-07-19 2023-07-19 GP130 antigen-binding molecules

Country Status (2)

Country Link
GB (1) GB202311050D0 (en)
WO (1) WO2025017127A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331092A (en) * 2024-09-23 2025-01-21 科迈生物科技(苏州)有限公司 Antibodies for binding to human GP130 and their applications

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05304986A (en) * 1992-04-28 1993-11-19 Tosoh Corp Monoclonal antibody against gp130 protein
US5571513A (en) * 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
ES2929575T3 (en) 2011-06-06 2022-11-30 Novo Nordisk As therapeutic antibodies
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
MX2020006508A (en) 2017-12-18 2020-09-17 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof.
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
KR20210138579A (en) 2019-01-21 2021-11-19 싱가포르 헬스 서비시즈 피티이 엘티디 Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
US11813311B2 (en) 2019-05-03 2023-11-14 Singapore Health Services Pte Ltd. Treatment and prevention of metabolic diseases
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331092A (en) * 2024-09-23 2025-01-21 科迈生物科技(苏州)有限公司 Antibodies for binding to human GP130 and their applications

Also Published As

Publication number Publication date
WO2025017127A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
SG11202105302PA (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
SG11202102882YA (en) Antigen-binding molecule comprising altered antibody variable region
SG11202009515RA (en) Vista antigen-binding molecules
GB202311050D0 (en) GP130 antigen-binding molecules
IL290299A (en) Multispecific antigen-binding molecules for cell targeting and uses thereof
GB201814562D0 (en) Vista antigen-binding molecules
IL325040A (en) Uses of dll3-targeting multispecific antigen-binding molecules
GB202218388D0 (en) GP130 antigen-binding molecules
EP3928790A4 (en) CD3 ANTIGEN-BINDING FRAGMENT AND ITS USE
GB201709970D0 (en) Bispecific antigen-binding molecules
IL292698A (en) N-terminal scfv multispecific binding molecules
SG11202104264TA (en) Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
IL276253B1 (en) Bispecific antigen-binding molecules and methods of use
IL286918A (en) Bispecific antibody
EP4339213A4 (en) ANTIGEN-BINDING MOLECULES
IL325163A (en) Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
IL290050A (en) Bispecific antibody
IL318557A (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
GB202310962D0 (en) GP130 antigen-binding molecules
GB202408044D0 (en) gp130 antigen-binding molecules
IL284703A (en) Anandamide compounds
IL317637A (en) Anti-steap1 antigen-binding molecules and uses thereof
HK40126861A (en) Gp130 antigen-binding molecules
CA3274782A1 (en) Gp130 antigen-binding molecules
GB2592920B (en) Removable spacer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)